{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:29:16Z","timestamp":1787790556708,"version":"build-2784847793"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02861-0","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T17:48:31Z","timestamp":1749577711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advancement in tumor treating fields of mechanism, clinical applications, and future directions"],"prefix":"10.1007","volume":"16","author":[{"given":"Meiqi","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2861_CR1","doi-asserted-by":"publisher","unstructured":"Cronin KA, Scott S, Firth AU et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. 2022;128(24):4251-84.https:\/\/doi.org\/10.1002\/cncr.34479","DOI":"10.1002\/cncr.34479"},{"issue":"11","key":"2861_CR2","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663\u201376. https:\/\/doi.org\/10.1007\/s11033-023-08809-3.","journal-title":"Mol Biol Rep"},{"key":"2861_CR3","doi-asserted-by":"publisher","unstructured":"Gillessen S, Bossi A, Davis ID et al. Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer 2023;185:178\u2013215.https:\/\/doi.org\/10.1016\/j.ejca.2023.02.018","DOI":"10.1016\/j.ejca.2023.02.018"},{"issue":"4","key":"2861_CR4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.athoracsur.2023.06.004","volume":"116","author":"AL Potter","year":"2023","unstructured":"Potter AL, Costantino CL, Suliman RA, et al. Recurrence after complete resection for Non-Small cell lung Cancer in the National lung screening trial. Ann Thorac Surg. 2023;116(4):684\u201392. https:\/\/doi.org\/10.1016\/j.athoracsur.2023.06.004.","journal-title":"Ann Thorac Surg"},{"key":"2861_CR5","doi-asserted-by":"publisher","unstructured":"Zaborowska-Szmit M, Szmit S, Olszyna-Serementa M, et al. Beta blockers with statins may decrease all-cause mortality in patients with cardiovascular diseases and locally advanced unresectable non-small-cell lung cancer after chemoradiotherapy. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15041277.","DOI":"10.3390\/cancers15041277"},{"issue":"12","key":"2861_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.2217\/imt-2022-0287","volume":"15","author":"B Cetin","year":"2023","unstructured":"Cetin B, Wabl CA, Gumusay O. Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers. Immunotherapy. 2023;15(12):945\u201362. https:\/\/doi.org\/10.2217\/imt-2022-0287.","journal-title":"Immunotherapy"},{"key":"2861_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.25259\/sni_674_2023","volume":"14","author":"A Colamaria","year":"2023","unstructured":"Colamaria A, Leone A, Fochi NP, et al. Tumor treating fields for the treatment of glioblastoma: current Understanding and future perspectives. Surg Neurol Int. 2023;14:394. https:\/\/doi.org\/10.25259\/sni_674_2023.","journal-title":"Surg Neurol Int"},{"key":"2861_CR8","doi-asserted-by":"publisher","first-page":"108287","DOI":"10.1016\/j.bioelechem.2022.108287","volume":"149","author":"C Pohling","year":"2023","unstructured":"Pohling C, Nguyen H, Chang E, et al. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy. Bioelectrochemistry. 2023;149:108287. https:\/\/doi.org\/10.1016\/j.bioelechem.2022.108287.","journal-title":"Bioelectrochemistry"},{"issue":"48","key":"2861_CR9","doi-asserted-by":"publisher","first-page":"e36421","DOI":"10.1097\/md.0000000000036421","volume":"102","author":"G Olatunji","year":"2023","unstructured":"Olatunji G, Aderinto N, Adefusi T, et al. Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence. Med (Baltim). 2023;102(48):e36421. https:\/\/doi.org\/10.1097\/md.0000000000036421.","journal-title":"Med (Baltim)"},{"issue":"9","key":"2861_CR10","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1158\/0008-5472.can-04-0083","volume":"64","author":"ED Kirson","year":"2004","unstructured":"Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288\u201395. https:\/\/doi.org\/10.1158\/0008-5472.can-04-0083.","journal-title":"Cancer Res"},{"issue":"1","key":"2861_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12094-024-03551-z","volume":"27","author":"T Xiao","year":"2025","unstructured":"Xiao T, Zheng H, Zu K, Yue Y, Wang Y. Tumor-treating fields in cancer therapy: advances of cellular and molecular mechanisms. Clin Transl Oncol. 2025;27(1):1\u201314. https:\/\/doi.org\/10.1007\/s12094-024-03551-z.","journal-title":"Clin Transl Oncol"},{"key":"2861_CR12","doi-asserted-by":"publisher","first-page":"107881doi","DOI":"10.1016\/j.bioelechem.2021.107881","volume":"141","author":"T Pfeifer","year":"2021","unstructured":"Pfeifer T, Bai L, Gladkich J, et al. Therapy of pancreatic cancer with alternating electric fields: limitations of the method. Bioelectrochemistry. 2021;141:107881. https:\/\/doi.org\/10.1016\/j.bioelechem.2021.107881.","journal-title":"Bioelectrochemistry"},{"key":"2861_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.critrevonc.2017.01.005","volume":"111","author":"M Mehta","year":"2017","unstructured":"Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol. 2017;111:60\u20135. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.01.005.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"2861_CR14","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/s1470-2045(19)30532-7","volume":"20","author":"GL Ceresoli","year":"2019","unstructured":"Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20(12):1702\u20139. https:\/\/doi.org\/10.1016\/s1470-2045(19)30532-7.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2861_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pan.2018.10.004","volume":"19","author":"F Rivera","year":"2019","unstructured":"Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopez-Martin J, Kung M. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study. Pancreatology. 2019;19(1):64\u201372. https:\/\/doi.org\/10.1016\/j.pan.2018.10.004.","journal-title":"Pancreatology"},{"key":"2861_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2147\/ppa.S296747","volume":"15","author":"BA Martinez-Cannon","year":"2021","unstructured":"Martinez-Cannon BA, Castro-Sanchez A, Barragan-Carrillo R, et al. Adherence to adjuvant Tamoxifen in Mexican young women with breast Cancer. Patient Prefer Adherence. 2021;15:1039\u201349. https:\/\/doi.org\/10.2147\/ppa.S296747.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"2861_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.lungcan.2013.06.025","volume":"81","author":"M Pless","year":"2013","unstructured":"Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I\/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013;81(3):445\u201350. https:\/\/doi.org\/10.1016\/j.lungcan.2013.06.025.","journal-title":"Lung Cancer"},{"issue":"3","key":"2861_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ygyno.2018.07.018","volume":"150","author":"I Vergote","year":"2018","unstructured":"Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor treating fields in combination with Paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study. Gynecol Oncol. 2018;150(3):471\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.018.","journal-title":"Gynecol Oncol"},{"key":"2861_CR19","doi-asserted-by":"publisher","unstructured":"Lan Y, Zhang S, Pan Y, Wang M, Chen G. Research progress on the mechanism of Anti-Tumor immune response induced by TTFields. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15235642.","DOI":"10.3390\/cancers15235642"},{"issue":"1","key":"2861_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neo.2020.11.003","volume":"23","author":"CB Patel","year":"2021","unstructured":"Patel CB, Beinat C, Xie Y, Chang E, Gambhir SS. Tumor treating fields (TTFields) impairs aberrant Glycolysis in glioblastoma as evaluated by [(18)F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression. Neoplasia. 2021;23(1):58\u201367. https:\/\/doi.org\/10.1016\/j.neo.2020.11.003.","journal-title":"Neoplasia"},{"issue":"6","key":"2861_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.21037\/cco-23-82","volume":"12","author":"T Kutuk","year":"2023","unstructured":"Kutuk T, Atak E, La Rosa A, Kotecha R, Mehta MP, Chuong MD. Tumor treating fields: narrative review of a promising treatment modality for cancer. Chin Clin Oncol. 2023;12(6):64. https:\/\/doi.org\/10.21037\/cco-23-82.","journal-title":"Chin Clin Oncol"},{"key":"2861_CR22","doi-asserted-by":"crossref","unstructured":"Bomzon Z, Wenger C, Proescholdt M, Mohan S, Tumor-Treating Fields EMBC. 2019: A Roadmap to Developing a Framework for TTFields Dosimetry and Treatment Planning. In: Makarov SN, Noetscher GM, Nummenmaa A, editors. Brain and Human Body Modeling 2020: Computational Human Models Presented at EMBC 2019 and the BRAIN Initiative\u00ae 2019 Meeting. Cham (CH): Springer Copyright 2021, The Author(s). 2021. pp. 3\u201317.","DOI":"10.1007\/978-3-030-45623-8_1"},{"key":"2861_CR23","doi-asserted-by":"publisher","unstructured":"Branter J, Estevez-Cebrero M, Diksin M, et al. Genome-Wide expression and Anti-Proliferative effects of electric field therapy on pediatric and adult brain tumors. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23041982.","DOI":"10.3390\/ijms23041982"},{"issue":"1","key":"2861_CR24","first-page":"71","volume":"36","author":"HU Xu","year":"2016","unstructured":"Xu HU, Bihari F, Whitehead S, Wong E, Schmid S, Hebb MO. In vitro validation of intratumoral modulation therapy for glioblastoma. Anticancer Res. 2016;36(1):71\u201380.","journal-title":"Anticancer Res"},{"key":"2861_CR25","doi-asserted-by":"publisher","unstructured":"Zhu W, Wang J, Luo H, et al. Electrical characterization and analysis of single cells and related applications. Biosens (Basel). 2023. https:\/\/doi.org\/10.3390\/bios13100907.","DOI":"10.3390\/bios13100907"},{"issue":"8","key":"2861_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2174\/1871527319666200702144749","volume":"19","author":"C Kissling","year":"2020","unstructured":"Kissling C, Di Santo S. Tumor treating fields-behind and beyond inhibiting the cancer cell cycle. CNS Neurol Disord Drug Targets. 2020;19(8):599\u2013610. https:\/\/doi.org\/10.2174\/1871527319666200702144749.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"20","key":"2861_CR27","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/0008-5472.Can-22-0887","volume":"82","author":"JC Moser","year":"2022","unstructured":"Moser JC, Salvador E, Deniz K, et al. The mechanisms of action of tumor treating fields. Cancer Res. 2022;82(20):3650\u20138. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-0887.","journal-title":"Cancer Res"},{"issue":"1","key":"2861_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13008-024-00109-x","volume":"19","author":"IS Tyagi","year":"2024","unstructured":"Tyagi IS, Tsui HYC, Chen S, et al. Non-mitotic proliferation of malignant cancer cells revealed through live-cell imaging of primary and cell-line cultures. Cell Div. 2024;19(1):3. https:\/\/doi.org\/10.1186\/s13008-024-00109-x.","journal-title":"Cell Div"},{"issue":"8","key":"2861_CR29","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1080\/09553002.2020.1837984","volume":"97","author":"NK Karanam","year":"2021","unstructured":"Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating Fields-induced cancer cell death and their clinical implications. Int J Radiat Biol. 2021;97(8):1044\u201354. https:\/\/doi.org\/10.1080\/09553002.2020.1837984.","journal-title":"Int J Radiat Biol"},{"key":"2861_CR30","doi-asserted-by":"publisher","first-page":"1274587","DOI":"10.3389\/fonc.2023.1274587","volume":"13","author":"K Szklener","year":"2023","unstructured":"Szklener K, Bilski M, Nieoczym K, Ma\u0144dziuk D, Ma\u0144dziuk S. Enhancing glioblastoma treatment through the integration of tumor-treating fields. Front Oncol. 2023;13:1274587. https:\/\/doi.org\/10.3389\/fonc.2023.1274587.","journal-title":"Front Oncol"},{"key":"2861_CR31","doi-asserted-by":"publisher","unstructured":"Le HT, Staelens M, Lazzari D, Chan G, Tuszy\u0144ski JA. Real-Time monitoring of the effect of Tumour-Treating fields on cell division using Live-Cell imaging. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11172712.","DOI":"10.3390\/cells11172712"},{"key":"2861_CR32","doi-asserted-by":"publisher","first-page":"738801","DOI":"10.3389\/fonc.2021.738801","volume":"11","author":"L Bai","year":"2021","unstructured":"Bai L, Pfeifer T, Gross W, et al. Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic Cancer. Front Oncol. 2021;11:738801. https:\/\/doi.org\/10.3389\/fonc.2021.738801.","journal-title":"Front Oncol"},{"issue":"40","key":"2861_CR33","doi-asserted-by":"publisher","first-page":"65125","DOI":"10.18632\/oncotarget.11372","volume":"7","author":"EH Kim","year":"2016","unstructured":"Kim EH, Song HS, Yoo SH, Yoon M. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. Oncotarget. 2016;7(40):65125\u201336. https:\/\/doi.org\/10.18632\/oncotarget.11372.","journal-title":"Oncotarget"},{"key":"2861_CR34","doi-asserted-by":"publisher","unstructured":"Voloshin T, Schneiderman RS, Volodin A, et al. Tumor treating fields (TTFields) hinder Cancer cell motility through regulation of microtubule and acting dynamics. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12103016.","DOI":"10.3390\/cancers12103016"},{"issue":"2","key":"2861_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11060-024-04740-0","volume":"169","author":"M Strack","year":"2024","unstructured":"Strack M, K\u00fcckelhaus J, Diebold M, et al. Effects of tumor treating fields (TTFields) on human mesenchymal stromal cells. J Neurooncol. 2024;169(2):329\u201340. https:\/\/doi.org\/10.1007\/s11060-024-04740-0.","journal-title":"J Neurooncol"},{"key":"2861_CR36","doi-asserted-by":"publisher","unstructured":"Aseervatham J. Cytoskeletal remodeling in Cancer. Biology (Basel). 2020. https:\/\/doi.org\/10.3390\/biology9110385.","DOI":"10.3390\/biology9110385"},{"issue":"6","key":"2861_CR37","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3171\/2022.8.Peds22300","volume":"30","author":"RT Nitta","year":"2022","unstructured":"Nitta RT, Luo EJ, Lim M, Li G. Can tumor treating fields induce DNA damage and reduce cell motility in Medulloblastoma cell lines? J Neurosurg Pediatr. 2022;30(6):555\u201366. https:\/\/doi.org\/10.3171\/2022.8.Peds22300.","journal-title":"J Neurosurg Pediatr"},{"key":"2861_CR38","doi-asserted-by":"publisher","first-page":"153303382094748","DOI":"10.1177\/1533033820947481","volume":"19","author":"JY Oh","year":"2020","unstructured":"Oh JY, Lee YJ, Kim EH. Tumor-Treating fields inhibit the metastatic potential of osteosarcoma cells. Technol Cancer Res Treat. 2020;19:1533033820947481. https:\/\/doi.org\/10.1177\/1533033820947481.","journal-title":"Technol Cancer Res Treat"},{"key":"2861_CR39","doi-asserted-by":"publisher","first-page":"715031","DOI":"10.3389\/fonc.2021.715031","volume":"11","author":"B Linder","year":"2021","unstructured":"Linder B, Schiesl A, Voss M, et al. Dexamethasone treatment limits efficacy of radiation, but does not interfere with glioma cell death induced by tumor treating fields. Front Oncol. 2021;11:715031. https:\/\/doi.org\/10.3389\/fonc.2021.715031.","journal-title":"Front Oncol"},{"key":"2861_CR40","doi-asserted-by":"publisher","unstructured":"Porat Y, Giladi M, Schneiderman RS et al. Determining the optimal inhibitory frequency for cancerous cells using tumor treating fields (TTFields). J Vis Exp. 2017(123).https:\/\/doi.org\/10.3791\/55820","DOI":"10.3791\/55820"},{"issue":"4","key":"2861_CR41","doi-asserted-by":"publisher","first-page":"e2753","DOI":"10.1038\/cddis.2017.171","volume":"8","author":"M Silginer","year":"2017","unstructured":"Silginer M, Weller M, Stupp R, Roth P. Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis. 2017;8(4):e2753. https:\/\/doi.org\/10.1038\/cddis.2017.171.","journal-title":"Cell Death Dis"},{"key":"2861_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2021.08.011","volume":"160","author":"H Mumblat","year":"2021","unstructured":"Mumblat H, Martinez-Conde A, Braten O, et al. Tumor treating fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models. Lung Cancer. 2021;160:99\u2013110. https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.011.","journal-title":"Lung Cancer"},{"issue":"12","key":"2861_CR43","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1080\/09553002.2020.1838658","volume":"96","author":"Y Jo","year":"2020","unstructured":"Jo Y, Oh G, Gi Y, et al. Tumor treating fields (TTF) treatment enhances radiation-induced apoptosis in pancreatic cancer cells. Int J Radiat Biol. 2020;96(12):1528\u201333. https:\/\/doi.org\/10.1080\/09553002.2020.1838658.","journal-title":"Int J Radiat Biol"},{"key":"2861_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41420-018-0079-9","volume":"4","author":"AF Kessler","year":"2018","unstructured":"Kessler AF, Fr\u00f6mbling GE, Gross F, et al. Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint Inhibition. Cell Death Discov. 2018;4:12. https:\/\/doi.org\/10.1038\/s41420-018-0079-9.","journal-title":"Cell Death Discov"},{"issue":"12","key":"2861_CR45","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/cns.13750","volume":"27","author":"H Wu","year":"2021","unstructured":"Wu H, Yang L, Liu H, et al. Exploring the efficacy of tumor electric field therapy against glioblastoma: an in vivo and in vitro study. CNS Neurosci Ther. 2021;27(12):1587\u2013604. https:\/\/doi.org\/10.1111\/cns.13750.","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"2861_CR46","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","volume":"69","author":"T Voloshin","year":"2020","unstructured":"Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTFields) induce Immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020;69(7):1191\u2013204. https:\/\/doi.org\/10.1007\/s00262-020-02534-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2861_CR47","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10585-009-9262-y","volume":"26","author":"ED Kirson","year":"2009","unstructured":"Kirson ED, Giladi M, Gurvich Z, et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633\u201340. https:\/\/doi.org\/10.1007\/s10585-009-9262-y.","journal-title":"Clin Exp Metastasis"},{"key":"2861_CR48","doi-asserted-by":"publisher","unstructured":"Lee J, Grabowski MM, Lathia JD. Tumor treating fields: killing two birds with one stone. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/jci159073.","DOI":"10.1172\/jci159073"},{"key":"2861_CR49","doi-asserted-by":"publisher","unstructured":"Chen D, Le SB, Hutchinson TE, et al. Tumor treating fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/jci149258.","DOI":"10.1172\/jci149258"},{"key":"2861_CR50","doi-asserted-by":"publisher","unstructured":"Barsheshet Y, Voloshin T, Brant B, et al. Tumor treating fields (TTFields) concomitant with immune checkpoint inhibitors are therapeutically effective in Non-Small cell lung Cancer (NSCLC) in vivo model. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232214073.","DOI":"10.3390\/ijms232214073"},{"issue":"11","key":"2861_CR51","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1038\/s41416-023-02454-0","volume":"129","author":"A Vanderlinden","year":"2023","unstructured":"Vanderlinden A, Jones CG, Myers KN, Rominiyi O, Collis SJ. DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells. Br J Cancer. 2023;129(11):1829\u201340. https:\/\/doi.org\/10.1038\/s41416-023-02454-0.","journal-title":"Br J Cancer"},{"key":"2861_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2019.10.003","volume":"217","author":"NK Karanam","year":"2020","unstructured":"Karanam NK, Ding L, Aroumougame A, Story MD. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: implications for cancer therapy. Transl Res. 2020;217:33\u201346. https:\/\/doi.org\/10.1016\/j.trsl.2019.10.003.","journal-title":"Transl Res"},{"key":"2861_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2019.10.003","volume":"217","author":"NK Karanam","year":"2020","unstructured":"Karanam NK, Ding L, Aroumougame A, Story MD. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: implications for cancer therapy. Translational Res. 2020;217:33\u201346. https:\/\/doi.org\/10.1016\/j.trsl.2019.10.003.","journal-title":"Translational Res"},{"key":"2861_CR54","doi-asserted-by":"publisher","first-page":"113doi","DOI":"10.1038\/s41420-018-0130-x","volume":"4","author":"E Chang","year":"2018","unstructured":"Chang E, Patel CB, Pohling C, et al. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discov. 2018;4:113doi. https:\/\/doi.org\/10.1038\/s41420-018-0130-x.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2861_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1152\/physrev.00050.2017","volume":"99","author":"MD Sweeney","year":"2019","unstructured":"Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-Brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21\u201378. https:\/\/doi.org\/10.1152\/physrev.00050.2017.","journal-title":"Physiol Rev"},{"issue":"4","key":"2861_CR56","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cpt.2545","volume":"111","author":"ECM de Lange","year":"2022","unstructured":"de Lange ECM, Hammarlund Udenaes M. Understanding the Blood-Brain barrier and beyond: challenges and opportunities for novel CNS therapeutics. Clin Pharmacol Ther. 2022;111(4):758\u201373. https:\/\/doi.org\/10.1002\/cpt.2545.","journal-title":"Clin Pharmacol Ther"},{"key":"2861_CR57","doi-asserted-by":"publisher","unstructured":"Salvador E, K\u00f6ppl T, H\u00f6rmann J, et al. Tumor treating fields (TTFields) induce cell junction alterations in a human 3D in vitro model of the Blood-Brain barrier. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15010185.","DOI":"10.3390\/pharmaceutics15010185"},{"key":"2861_CR58","doi-asserted-by":"publisher","unstructured":"Salvador E, Kessler AF, Domr\u00f6se D, et al. Tumor treating fields (TTFields) reversibly permeabilize the Blood-Brain barrier in vitro and in vivo. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12101348.","DOI":"10.3390\/biom12101348"},{"key":"2861_CR59","doi-asserted-by":"publisher","unstructured":"Rahman MA, Saikat ASM, Rahman MS, Islam M, Parvez MAK, Kim B. Recent update and drug target in molecular and Pharmacological insights into autophagy modulation in Cancer treatment and future progress. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12030458.","DOI":"10.3390\/cells12030458"},{"issue":"11","key":"2861_CR60","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s41419-018-1085-9","volume":"9","author":"A Shteingauz","year":"2018","unstructured":"Shteingauz A, Porat Y, Voloshin T, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to tumor treating fields (TTFields). Cell Death Dis. 2018;9(11):1074. https:\/\/doi.org\/10.1038\/s41419-018-1085-9.","journal-title":"Cell Death Dis"},{"key":"2861_CR61","doi-asserted-by":"publisher","unstructured":"Lee YJ, Cho JM, Sai S, et al. 5-Fluorouracil as a Tumor-Treating Field-Sensitizer in Colon cancer therapy. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11121999.","DOI":"10.3390\/cancers11121999"},{"issue":"39","key":"2861_CR62","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.1038\/s41388-019-0882-7","volume":"38","author":"EH Kim","year":"2019","unstructured":"Kim EH, Jo Y, Sai S, et al. Tumor-treating fields induce autophagy by blocking the Akt2\/miR29b axis in glioblastoma cells. Oncogene. 2019;38(39):6630\u201346. https:\/\/doi.org\/10.1038\/s41388-019-0882-7.","journal-title":"Oncogene"},{"issue":"12","key":"2861_CR63","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s00066-023-02122-5","volume":"199","author":"B Frey","year":"2023","unstructured":"Frey B, Borgmann K, Jost T, et al. DNA as the main target in radiotherapy-a historical overview from first isolation to anti-tumour immune response. Strahlenther Onkol. 2023;199(12):1080\u201390. https:\/\/doi.org\/10.1007\/s00066-023-02122-5.","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"2861_CR64","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13014-017-0941-6","volume":"12","author":"M Giladi","year":"2017","unstructured":"Giladi M, Munster M, Schneiderman RS, et al. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol. 2017;12(1):206. https:\/\/doi.org\/10.1186\/s13014-017-0941-6.","journal-title":"Radiat Oncol"},{"issue":"9","key":"2861_CR65","first-page":"4582","volume":"11","author":"WS Lee","year":"2021","unstructured":"Lee WS, Seo SJ, Chung HK, Park JW, Kim JK, Kim EH. Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy. Am J Cancer Res. 2021;11(9):4582\u201394.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"2861_CR66","doi-asserted-by":"publisher","first-page":"e2711","DOI":"10.1038\/cddis.2017.136","volume":"8","author":"NK Karanam","year":"2017","unstructured":"Karanam NK, Srinivasan K, Ding L, Sishc B, Saha D, Story MD. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. Cell Death Dis. 2017;8(3):e2711. https:\/\/doi.org\/10.1038\/cddis.2017.136.","journal-title":"Cell Death Dis"},{"key":"2861_CR67","doi-asserted-by":"crossref","unstructured":"Jo Y, Kim EH, Sai S et al. Functional biological activity of Sorafenib as a Tumor-Treating field sensitizer for glioblastoma therapy. Int J Mol Sci. 2018;19(11):3684.","DOI":"10.3390\/ijms19113684"},{"key":"2861_CR68","doi-asserted-by":"crossref","unstructured":"Branter J, Estevez-Cebrero M, Diksin M et al. Genome-wide expression and anti-proliferative effects of electric field therapy on pediatric and adult brain tumors. Int J Mol Sci. 2022;23(4):1982.","DOI":"10.3390\/ijms23041982"},{"key":"2861_CR69","doi-asserted-by":"publisher","unstructured":"Kirson ED, Schneiderman RS, Dbal\u00fd V, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009. https:\/\/doi.org\/10.1186\/1756-6649-9-1.","DOI":"10.1186\/1756-6649-9-1"},{"key":"2861_CR70","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jocn.2016.10.042","volume":"36","author":"PA Clark","year":"2017","unstructured":"Clark PA, Gaal JT, Strebe JK, et al. The effects of tumor treating fields and Temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. J Clin Neurosci. 2017;36:120\u20134. https:\/\/doi.org\/10.1016\/j.jocn.2016.10.042.","journal-title":"J Clin Neurosci"},{"issue":"8","key":"2861_CR71","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41416-024-02608-8","volume":"130","author":"Q Cao","year":"2024","unstructured":"Cao Q, Hajosch A, Kast RE, et al. Tumor treating fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. Br J Cancer. 2024;130(8):1365\u201376. https:\/\/doi.org\/10.1038\/s41416-024-02608-8.","journal-title":"Br J Cancer"},{"issue":"3","key":"2861_CR72","doi-asserted-by":"publisher","first-page":"569","DOI":"10.7507\/1001-5515.202312063","volume":"41","author":"X Li","year":"2024","unstructured":"Li X, Liu K, Guo C, Fang T, Yang F. [Study on the mesoscopic dynamic effects of tumor treating fields on cell tubulin]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2024;41(3):569\u201376. https:\/\/doi.org\/10.7507\/1001-5515.202312063.","journal-title":"Sheng Wu Yi Xue Gong Cheng Xue Za Zhi"},{"issue":"12","key":"2861_CR73","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1002\/ijc.30406","volume":"139","author":"T Voloshin","year":"2016","unstructured":"Voloshin T, Munster M, Blatt R, et al. Alternating electric fields (TTFields) in combination with Paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer. 2016;139(12):2850\u20138. https:\/\/doi.org\/10.1002\/ijc.30406.","journal-title":"Int J Cancer"},{"key":"2861_CR74","doi-asserted-by":"publisher","first-page":"1402851","DOI":"10.3389\/fonc.2024.1402851","volume":"14","author":"Y Berckmans","year":"2024","unstructured":"Berckmans Y, Ene HM, Ben-Meir K, et al. Tumor treating fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance. Front Oncol. 2024;14:1402851. https:\/\/doi.org\/10.3389\/fonc.2024.1402851.","journal-title":"Front Oncol"},{"key":"2861_CR75","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.seminoncol.2014.09.006","volume":"41","author":"M Giladi","year":"2014","unstructured":"Giladi M, Weinberg U, Schneiderman RS, et al. Alternating electric fields (Tumor-Treating fields Therapy) can improve chemotherapy treatment efficacy in Non-Small cell lung cancer both in vitro and in vivo. Semin Oncol. 2014;41:S35\u201341. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.09.006.","journal-title":"Semin Oncol"},{"key":"2861_CR76","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","DOI":"10.3322\/caac.21820"},{"issue":"8","key":"2861_CR77","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.21037\/tcr-21-1853","volume":"11","author":"EH Kim","year":"2022","unstructured":"Kim EH, Lee WS, Oh HK. Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT\/STAT3 signaling. Transl Cancer Res. 2022;11(8):2553\u201361. https:\/\/doi.org\/10.21037\/tcr-21-1853.","journal-title":"Transl Cancer Res"},{"issue":"4","key":"2861_CR78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s10544-018-0339-8","volume":"20","author":"KF Lei","year":"2018","unstructured":"Lei KF, Hsieh SC, Goh A, Kuo RL, Tsang NM. Proliferation arrest, selectivity, and chemosensitivity enhancement of cancer cells treated by a low-intensity alternating electric field. Biomed Microdevices. 2018;20(4):90. https:\/\/doi.org\/10.1007\/s10544-018-0339-8.","journal-title":"Biomed Microdevices"},{"issue":"4","key":"2861_CR79","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3892\/ol.2022.13458","volume":"24","author":"Y Jang","year":"2022","unstructured":"Jang Y, Lee WS, Sai S, Kim JY, Kim JK, Kim EH. Tumor-treating fields in combination with Sorafenib restrain the proliferation of liver cancer in vitro. Oncol Lett. 2022;24(4):338. https:\/\/doi.org\/10.3892\/ol.2022.13458.","journal-title":"Oncol Lett"},{"issue":"8","key":"2861_CR80","first-page":"3935","volume":"11","author":"JS Kim","year":"2021","unstructured":"Kim JS, Cho JM, Kim H, Jeong YK, Kim JK, Kim EH. Tumor treating fields can effectively overcome trastuzumab resistant breast cancer multiplication. Am J Cancer Res. 2021;11(8):3935\u201345.","journal-title":"Am J Cancer Res"},{"key":"2861_CR81","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/1471-2407-10-229","volume":"10","author":"RS Schneiderman","year":"2010","unstructured":"Schneiderman RS, Shmueli E, Kirson ED, Palti Y. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. BMC Cancer. 2010;10:229. https:\/\/doi.org\/10.1186\/1471-2407-10-229.","journal-title":"BMC Cancer"},{"issue":"1","key":"2861_CR82","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pan.2013.11.009","volume":"14","author":"M Giladi","year":"2014","unstructured":"Giladi M, Schneiderman RS, Porat Y, et al. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology. 2014;14(1):54\u201363. https:\/\/doi.org\/10.1016\/j.pan.2013.11.009.","journal-title":"Pancreatology"},{"issue":"1","key":"2861_CR83","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12885-025-13859-w","volume":"25","author":"W Lin","year":"2025","unstructured":"Lin W, Wang Y, Li M, et al. Tumor treating fields enhance anti-PD therapy by improving CCL2\/8 and CXCL9\/CXCL10 expression through inducing Immunogenic cell death in NSCLC models. BMC Cancer. 2025;25(1):489. https:\/\/doi.org\/10.1186\/s12885-025-13859-w.","journal-title":"BMC Cancer"},{"issue":"12 Suppl 2","key":"2861_CR84","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2016\u20132020. Neuro Oncol. 2023;25(12 Suppl 2):iv1\u201399. https:\/\/doi.org\/10.1093\/neuonc\/noad149.","journal-title":"Neuro Oncol"},{"issue":"23","key":"2861_CR85","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating fields plus maintenance Temozolomide vs maintenance Temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 2017;318(23):2306\u201316. https:\/\/doi.org\/10.1001\/jama.2017.18718.","journal-title":"JAMA"},{"issue":"8","key":"2861_CR86","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a society for Neuro-Oncology (SNO) and European society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073\u2013113. https:\/\/doi.org\/10.1093\/neuonc\/noaa106.","journal-title":"Neuro Oncol"},{"issue":"24","key":"2861_CR87","doi-asserted-by":"publisher","first-page":"10152","DOI":"10.1073\/pnas.0702916104","volume":"104","author":"ED Kirson","year":"2007","unstructured":"Kirson ED, Dbal\u00fd V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104(24):10152\u20137. https:\/\/doi.org\/10.1073\/pnas.0702916104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"2861_CR88","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192\u2013202. https:\/\/doi.org\/10.1016\/j.ejca.2012.04.011.","journal-title":"Eur J Cancer"},{"issue":"23","key":"2861_CR89","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with Tumor-Treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: A randomized clinical trial. JAMA. 2015;314(23):2535\u201343. https:\/\/doi.org\/10.1001\/jama.2015.16669.","journal-title":"JAMA"},{"issue":"4","key":"2861_CR90","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","volume":"4","author":"MJB Taphoorn","year":"2018","unstructured":"Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with Tumor-Treating fields on Health-Related quality of life of patients with newly diagnosed glioblastoma: A secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495\u2013504. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5082.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2861_CR91","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/jjco\/hyad001","volume":"53","author":"R Nishikawa","year":"2023","unstructured":"Nishikawa R, Yamasaki F, Arakawa Y, et al. Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF system: a prospective post-approval study. Jpn J Clin Oncol. 2023;53(5):371\u20137. https:\/\/doi.org\/10.1093\/jjco\/hyad001.","journal-title":"Jpn J Clin Oncol"},{"issue":"15","key":"2861_CR92","first-page":"2","volume":"38","author":"J Fallah","year":"2020","unstructured":"Fallah J, Chaudhary RT, Rogers LR, et al. Clinical outcomes of the combination of bevacizumab and Ttfields in patients with recurrent glioblastoma: results of a phase II clinical trial. J Clin Oncol. 2020;38(15):2.","journal-title":"J Clin Oncol"},{"key":"2861_CR93","doi-asserted-by":"publisher","first-page":"896246","DOI":"10.3389\/fonc.2022.896246","volume":"12","author":"R Miller","year":"2022","unstructured":"Miller R, Song A, Ali A, et al. Scalp-Sparing radiation with concurrent Temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma. Front Oncol. 2022;12:896246. https:\/\/doi.org\/10.3389\/fonc.2022.896246.","journal-title":"Front Oncol"},{"key":"2861_CR94","doi-asserted-by":"publisher","unstructured":"Kutuk T, Appel H, Avendano MC, et al. Feasibility of tumor treating fields with pemetrexed and Platinum-Based chemotherapy for unresectable malignant pleural mesothelioma: Single-Center, Real-World data. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14082020.","DOI":"10.3390\/cancers14082020"},{"key":"2861_CR95","doi-asserted-by":"publisher","unstructured":"Gkika E, Grosu AL, Macarulla Mercade T, et al. Tumor treating fields concomitant with Sorafenib in advanced hepatocellular cancer: results of the HEPANOVA phase II study. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14061568.","DOI":"10.3390\/cancers14061568"},{"issue":"9","key":"2861_CR96","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s1470-2045(23)00344-3","volume":"24","author":"T Leal","year":"2023","unstructured":"Leal T, Kotecha R, Ramlau R, et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol. 2023;24(9):1002\u201317. https:\/\/doi.org\/10.1016\/s1470-2045(23)00344-3.","journal-title":"Lancet Oncol"},{"issue":"9, Supplement","key":"2861_CR97","doi-asserted-by":"publisher","first-page":"S377","DOI":"10.1016\/j.jtho.2022.07.648","volume":"17","author":"R Kotecha","year":"2022","unstructured":"Kotecha R, Langer CJ, Ernani V, Tsao A. EP08.01-076 KEYNOTE B36: A pilot study of First-line tumor treating fields (150\u00a0kHz) plus pembrolizumab for advanced or metastatic Non-small cell lung Cancer. J Thorac Oncol. 2022;17(9, Supplement):S377\u2013S. https:\/\/doi.org\/10.1016\/j.jtho.2022.07.648.","journal-title":"J Thorac Oncol"},{"key":"2861_CR98","doi-asserted-by":"publisher","unstructured":"Brozova H, Lucas A, Salmaggi A, Vymazal J. BMET-06COMET:, A PHASE II RANDOMIZED STUDY OF TTFIELDS VERSUS SUPPORTIVE CARE IN NON-SMALL CELL LUNG CANCER PATIENTS WITH. 1\u20135 BRAIN METASTASES - INITIAL SAFETY RESULTS. Neurooncology. 2015;17(suppl5):v46\u2013v. https:\/\/doi.org\/10.1093\/neuonc\/nov208.06.","DOI":"10.1093\/neuonc\/nov208.06"},{"issue":"15suppl","key":"2861_CR99","doi-asserted-by":"publisher","first-page":"TPS9106","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS9106","volume":"35","author":"MP Mehta","year":"2017","unstructured":"Mehta MP, Gondi V, Brown PD. METIS: A phase 3 study of radiosurgery with TTFields for 1\u201310 brain metastases from NSCLC. J Clin Oncol. 2017;35(15suppl):TPS9106. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.TPS9106.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2861_CR100","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primers"},{"key":"2861_CR101","doi-asserted-by":"publisher","first-page":"S1455","DOI":"10.1016\/j.annonc.2022.10.101","volume":"33","author":"J Li","year":"2022","unstructured":"Li J, Cang S, Ling Y, et al. LBA3 tumor treating fields (TTFields) therapy plus XELOX chemotherapy for front line treatment of advanced unresectable gastroesophageal junction adenocarcinoma (GEJC) or gastric adenocarcinoma (GC): A multicenter phase II trial. Ann Oncol. 2022;33:S1455. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.101.","journal-title":"Ann Oncol"},{"issue":"2","key":"2861_CR102","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/15368378.2020.1737804","volume":"39","author":"S Hossain","year":"2020","unstructured":"Hossain S. Biodielectric phenomenon for actively differentiating malignant and normal cells: an overview. Electromagn Biol Med. 2020;39(2):89\u201396. https:\/\/doi.org\/10.1080\/15368378.2020.1737804.","journal-title":"Electromagn Biol Med"},{"issue":"2","key":"2861_CR103","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/cam4.5037","volume":"12","author":"T Jin","year":"2023","unstructured":"Jin T, Dou Z, Zhao Y, et al. Skull defect increases the tumor treating fields strength without detrimental thermogenic effect: A computational simulating research. Cancer Med. 2023;12(2):1461\u201370. https:\/\/doi.org\/10.1002\/cam4.5037.","journal-title":"Cancer Med"},{"key":"2861_CR104","doi-asserted-by":"crossref","unstructured":"Mikic N, Korshoej AR. Improving Tumor-Treating Fields with Skull Remodeling Surgery, Surgery Planning, and Treatment Evaluation with Finite Element Methods. In: Makarov SN, Noetscher GM, Nummenmaa A, editors. Brain and Human Body Modeling 2020: Computational Human Models Presented at EMBC 2019 and the BRAIN Initiative\u00ae 2019 Meeting. Cham (CH): Springer Copyright 2021, The Author(s). 2021. pp. 63\u201377.","DOI":"10.1007\/978-3-030-45623-8_4"},{"issue":"5","key":"2861_CR105","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.04.008","volume":"104","author":"MT Ballo","year":"2019","unstructured":"Ballo MT, Urman N, Lavy-Shahaf G, Grewal J, Bomzon Ze, Toms S. Correlation of tumor treating fields dosimetry to survival outcomes in newly diagnosed glioblastoma: A Large-Scale numerical Simulation-Based analysis of data from the phase 3 EF-14 randomized trial. Int J Radiation Oncology*Biology*Physics. 2019;104(5):1106\u201313. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.04.008.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"2861_CR106","doi-asserted-by":"crossref","unstructured":"Urman N, Levy S, Frenkel A et al. Investigating the Connection Between Tumor-Treating Fields Distribution in the Brain and Glioblastoma Patient Outcomes. A Simulation-Based Study Utilizing a Novel Model Creation Technique. In: Makarov S, Horner M, Noetscher G, editorsBrain and Human Body Modeling: Computational Human Modeling at EMBC 2018. Cham (CH): Springer Copyright. 2019, The Author(s). 2019. pp. 139\u2009\u2013\u200954.","DOI":"10.1007\/978-3-030-21293-3_7"},{"issue":"4","key":"2861_CR107","doi-asserted-by":"publisher","first-page":"101203","DOI":"10.1016\/j.adro.2023.101203","volume":"8","author":"E Lok","year":"2023","unstructured":"Lok E, Liang O, Malik T, Wong ET. Computational analysis of tumor treating fields for Non-Small cell lung Cancer in full thoracic models. Adv Radiat Oncol. 2023;8(4):101203. https:\/\/doi.org\/10.1016\/j.adro.2023.101203.","journal-title":"Adv Radiat Oncol"},{"key":"2861_CR108","doi-asserted-by":"crossref","unstructured":"Korshoej AR. Estimation of TTFields intensity and anisotropy with singular value decomposition: a new and comprehensive method for dosimetry of TTFields. In: Makarov S, Horner M, Noetscher G, editors. Brain and Human Body Modeling: Computational Human Modeling at EMBC 2018. Cham: Springer; 2019. pp. 173\u2009\u201393.","DOI":"10.1007\/978-3-030-21293-3_10"},{"key":"2861_CR109","doi-asserted-by":"publisher","first-page":"909652","DOI":"10.3389\/fnhum.2022.909652","volume":"16","author":"F Cao","year":"2022","unstructured":"Cao F, Mikic N, Wong ET, Thielscher A, Korshoej AR. Guidelines for burr hole surgery in combination with tumor treating fields for glioblastoma: A computational study on dose optimization and array layout planning. Front Hum Neurosci. 2022;16:909652. https:\/\/doi.org\/10.3389\/fnhum.2022.909652.","journal-title":"Front Hum Neurosci"},{"key":"2861_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/cci.18.00066","volume":"3","author":"A Hawkins-Daarud","year":"2019","unstructured":"Hawkins-Daarud A, Johnston SK, Swanson KR. Quantifying uncertainty and robustness in a biomathematical model-based patient-specific response metric for glioblastoma. JCO Clin Cancer Inf. 2019;3:1\u20138. https:\/\/doi.org\/10.1200\/cci.18.00066.","journal-title":"JCO Clin Cancer Inf"},{"key":"2861_CR111","doi-asserted-by":"publisher","unstructured":"Jo Y, Kim EH, Sai S, et al. Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19113684.","DOI":"10.3390\/ijms19113684"},{"issue":"Suppl 6","key":"2861_CR112","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.seminoncol.2014.09.006","volume":"41","author":"M Giladi","year":"2014","unstructured":"Giladi M, Weinberg U, Schneiderman RS, et al. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin Oncol. 2014;41(Suppl 6):S35\u201341. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.09.006.","journal-title":"Semin Oncol"},{"key":"2861_CR113","doi-asserted-by":"publisher","unstructured":"Davidi S, Jacobovitch S, Shteingauz A, et al. Tumor treating fields (TTFields) concomitant with Sorafenib inhibit hepatocellular carcinoma in vitro and in vivo. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14122959.","DOI":"10.3390\/cancers14122959"},{"issue":"10","key":"2861_CR114","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1080\/13696998.2019.1614933","volume":"22","author":"GF Guzauskas","year":"2019","unstructured":"Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison LP. Jr. Tumor treating fields and maintenance Temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. J Med Econ. 2019;22(10):1006\u201313. https:\/\/doi.org\/10.1080\/13696998.2019.1614933.","journal-title":"J Med Econ"},{"issue":"2","key":"2861_CR115","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11060-024-04662-x","volume":"168","author":"Y Xiang","year":"2024","unstructured":"Xiang Y, Chen Y, Xu Z, et al. Real-world cost- effectiveness analysis: tumor treating fields for newly diagnosed glioblastoma in China. J Neurooncol. 2024;168(2):259\u201367. https:\/\/doi.org\/10.1007\/s11060-024-04662-x.","journal-title":"J Neurooncol"},{"key":"2861_CR116","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/ceor.S501532","volume":"17","author":"W Furnback","year":"2025","unstructured":"Furnback W, Wu E, Koh CYC, et al. Estimating the cost-effectiveness of tumor treating fields (TTFields) therapy with an immune checkpoint inhibitor or docetaxel in metastatic non-small cell lung cancer. Clinicoecon Outcomes Res. 2025;17:55\u201368. https:\/\/doi.org\/10.2147\/ceor.S501532.","journal-title":"Clinicoecon Outcomes Res"},{"key":"2861_CR117","doi-asserted-by":"publisher","first-page":"1276049","DOI":"10.3389\/fpubh.2024.1276049","volume":"12","author":"Z Pei","year":"2024","unstructured":"Pei Z, Xiao N, Yang P. Cost-effectiveness analysis of tumor treating fields treatment in Chinese patients with metastatic non-small cell lung cancer. Front Public Health. 2024;12:1276049. https:\/\/doi.org\/10.3389\/fpubh.2024.1276049.","journal-title":"Front Public Health"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02861-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T17:48:36Z","timestamp":1749577716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02861-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":117,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2861"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02861-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"1049"}}